CANbridge Pharmaceuticals

company

About

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare .

  • 101 - 250

Details

Last Funding Type
Series E
Last Funding Money Raised
$43M
Industries
Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2012
Number Of Employee
101 - 250
Operating Status
Active

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$43M
CANbridge Pharmaceuticals has raised a total of $43M in funding over 2 rounds. Their latest funding was raised on Dec 1, 2020 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 1, 2020 Series E $43M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
CANbridge Pharmaceuticals is funded by 1 investors. Hangzhou Zhiyan Dongli Jishu Management Consulting are the most recent investors.
Investor Name Lead Investor Funding Round
Hangzhou Zhiyan Dongli Jishu Management Consulting Series E